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Abstract: A paradoxical metabolic imbalance in inorganic phosphate occurs from the early 
onset of diabetes and may lead to a reduction of high energy phosphates and tissue hypoxia. 
These changes take place in the cells and tissues in which the entry of glucose is not controlled 
by insulin, and particularly in poorly regulated diabetes patients in whom long-term vascular 
complications are more likely to occur. Several therapeutic intervention trials have been carried 
out, including assessment of optimal glucose regulation, the effect of dietary inclusion of calcium 
diphosphate and pharmaceutical intake of etidronate disodium (EHDP), but none of these 
modalities wholly overcome the problem. The potential therapeutic application of fructose-1, 
6-diphosphate, however, which also acts as human bioenergy, holds a great deal of promise as 
an efficacious and well-tolerated therapeutic regimen.
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Diabetes mellitus is the most common human metabolic disorder, and a major health 
concern is the severe morbidity and mortality of the late diabetic complications. In our 
efforts to elucidate the mechanisms leading to the early functional changes in the 
retina and kidneys of diabetes patients, we noted repeated evidence of a disturbance 
in the metabolism of inorganic phosphate (Pi).1–6 Phylogenetic, experimental and 
clinical research data in nondiabetic conditions strongly suggests that the plasma 
and/or intracellular concentration of Pi may be a determining factor in regulation of 
energy metabolism and rate of oxygen consumption.7–13 Diabetes mellitus, however, 
demonstrates the opposite behavior, in that the highest oxygen consumption is 
associated with the lowest content of inorganic phosphate, and lowering oxygen 
consumption is associated with higher concentration of inorganic phosphate. Since 
a reduction of high energy phosphates and tissue hypoxia may be important factors 
in the development of long-term diabetic complications (DLC), the effects of Pi on 
the metabolism and function of the erythrocyte and renal tubular cell, as well as local 
and systemic consequences of severe hypophosphatemia in and during recovery 
from diabetic ketoacidosis, have recently been reviewed (J Ditzel and HH Lervang, 
unpublished data). The results indicate, that most conventionally treated diabetic 
patients respond as if their tissues are in a state of chronic hypoxia and suggesting that 
erythropoietin (EPO) is stimulated at an early stage in diabetes. A major disturbance in 
phosphate handling occurs in the kidney tubules, where the excessive sodium-dependent 
glucose reabsorption in diabetics depolarizes the electrochemical sodium gradient. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 174
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Since Pi use the same driving force, but have less binding 
to sodium than glucose and amino acids such as alanine, the 
Pi reabsorption, particularly in poorly regulated patients, 
becomes impaired. This paradoxical phosphate imbalance 
may lead to affinity hypoxia and impaired formation of 
high energy phosphates. The lack of intracellular phosphate 
complementary to the increased intracellular glucose takes 
place in the insulin-insensitive cells and tissues, resulting in 
the possibility of DLC.
Many of the obvious dietary and pharmacological routes 
explored thus far to overcome this problem are evaluated 
herein.
Effect of optimal blood glucose 
control
Many investigators have found decreased concentrations of 
Pi in poorly regulated diabetic patients and slightly elevated 
levels when optimally controlled.
In newly diagnosed, nonacidotic insulin-dependent 
diabetic patient’s plasma Pi concentration was normal at 
admission, showed lower range on the day after initial insulin 
administration and slightly above normal level on the day 
of best metabolic control. Red cell 2, 3-diphosphoglycerate 
(2, 3-DPG) exhibited the same fluctuating pattern, and 
Pi correlated closely to 2, 3-DPG (r = 0.61; P  0.001). 
Red cell 2, 3-DPG concentration correlated equally well 
with P50 (oxygen tension at 50% oxygen saturation) of the 
oxyhemoglobin dissociation curve (ODC).14,15
Gertner et al16 studied mineral metabolism in 7 juvenile-
onset diabetic patients before and after achieving near-
normal glucose levels by 7 to 14 days treatment with 
a portable subcutaneous insulin infusion system. They 
found that as plasma glucose decreased from an average 
of 221 mg/dL to 95.9 mg/dL, serum Pi rose from 4.09 
to 5.01 mg/dL (P  0.001) due to a 25% rise in renal 
tubular threshold for phosphate. No change was noted in 
immunoreactive parathyroid hormone (PTH) and in 1, 25 
hydroxy-vitamin D.
Ditzel et al4 studied renal handling of Pi in 26 conventionally 
treated diabetic children vs 28 healthy children and found 
fasting urinary phosphate excretion 3 times higher in the former 
group despite a significantly lower fasting Pi. The maximal 
capacity of renal tubular reabsorption of phosphate per liter 
of filtrate (TmPO4/GFR) was significantly suppressed in the 
diabetic patients. The increased urinary phosphate excretion 
correlated positively with both urinary glucose excretion and 
blood glucose concentration (P  0.01). This finding was 
unrelated to serum PTH or to plasma growth hormone.
Raskin and Pak17 studied 21 diabetic patients in whom 
treatment results ranged from “suboptimal” to “optimal” 
control and found that, as the mean plasma glucose 
decreased from 17.1 mmol/L to 5.2 mmol/L over 4 to 10 
days, serum phosphate level rose from 1.12 to 1.26 mmol/L 
(P  0.001).
The same significant increase in Pi was found in 
28 patients with type 2 diabetes who were examined both 
at admission when their disease was poorly controlled and 
following several days of hospitalization and treatment had 
markedly improved their metabolic status. In these patients, 
serum Pi levels increased significantly from 1.12 mmol/L 
to 1.21 mmol/L (P  0.01), while serum calcium remained 
unchanged and urinary calcium and phosphorous excretion 
both decreased. On admission urinary calcium and phospho-
rous excretions showed a positive correlation with glucose 
excretion. Serum PTH decreased from a mid-normal to a 
low-normal value.18
Thus, in both type 1 and type 2 diabetes, there is a close 
correlation between the Pi concentration in plasma and 
an improvement in diabetes control and in intracellular 
phosphate with a stimulating influence on the rate of cell 
glycolysis.
Effect of dietary phosphate intake
Pi concentration may also be increased by increasing dietary 
phosphate. Adding 2 g of calcium diphosphate to the three main 
daily meals over 4 weeks resulted in increased mean content of 
intraerythrocytic-2, 3-DPG and in the P50 of the ODC in both 
juvenile and adult diabetes patients.19 To determine whether 
the immediate effect of increased phosphate intake persisted 
a subsequent double-masked, placebo-controlled study was 
undertaken for 1 year to assess renal processing of phosphate 
and bone mineral content in 43 juvenile type 1 diabetic 
patients. No increase was seen in the concentration of Pi 
(active n = 19: 1.33 mmol/L vs placebo; n = 24: 1.42 mmol/L, 
P = ns).20 In the treatment group, the fasting urinary phos-
phate excretion increased as compared to the placebo group 
(median 1.28 vs 1.01 mmol/h; P  0.001) and phosphate 
clearance/GFR was significantly enhanced (0.16 vs 0.10; 
P  0.001). The threshold concentration of phosphate 
(TmPO4//GFR) was suppressed (1.19 vs 1.42 mmol/L; 
P  0.01) in the treatment vs placebo group, and in contrast 
to the controls (1.81 vs 1.42 mmol/L; P  0.001) (Figure 1).
The threshold concentration TmPO4/GFR was not related 
to the level of parathyroid hormone or to growth hormone 
level in serum, but inversely correlated with the degree 
of hyperglycemia. No difference in bone mineral content Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 175
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Figure 1 The phosphate threshold concentration, which is numerically equal to 
maximum tubular reabsorption rate for phosphate per unit volume of glomerular 
filtrate in 28 healthy children (1.81 mmol/L) vs 24 conventionally treated diabetic 
children without microvascular complications (1.42 mmol/L) and 19 diabetic children 
whom received 6 grams of calcium diphosphate daily for one year (1.19 mmol/L).
was found between the treatment and placebo groups. These 
observations demonstrate that the dysfunction of the tubular 
handling of phosphate in diabetic children associated with 
hyperglycemia cannot be compensated for by daily dietary 
supplements of calcium diphosphate.
Effect of etidronate disodium 
(EHDP)
Intake of the diphosphonate, ethane-1, 1-diphosphonate 
(EHDP) is known to produce sustained hyperphosphatemia.21–23 
This rise in Pi concentration occurs without a corresponding 
increase in urinary phosphate excretion, suggesting that EHDP 
partly elevates Pi by reducing its renal clearance. To study the 
effect of prolonged elevation of Pi on red cell metabolism and 
function, oxyhemoglobin dissociation curves (ODC) from 
zero to full saturation were performed on whole blood from 
14 insulin-treated, nonacidotic diabetes patients and 5 healthy 
volunteers following oral intake of EHDP ( 20 mg kg–1day–1) 
or placebo for 28 days.24 The mean Pi increased from 1.18 
to 1.57 mmol/L (P  0.001) in the diabetes patients and 
from 1.14 to 1.69 mmol/L (P  0.005) in healthy controls. 
A significant rise in red cell 2, 3-DPG was seen only in the 
diabetic group from 15.2 to 16.3 mmol/g of hemoglobin 
(P  0.005) and probably indicates a suppression of the 
2, 3-DPG formation pathway in diabetes patients. However, 
there was a significant relationship between the concentration 
of Pi and the P50 of the ODC in both diabetics (r = 0.58, 
P  0.01) and healthy controls (r = 0.69, P  0.005). 
Mean P50 in diabetic patients was significantly lower than 
controls despite normal 2, 3-DPG. The study empha-
sizes the importance of Pi on red cell function and indi-
cates that elevated Pi tends to counteract the defect in 
oxygen-release capacity of the erythrocytes in diabetes 
patients. A subsequent randomized, 6-month, double-blind 
study of 26 type 1 diabetic patients with nonproliferative 
retinopathy confirmed the effect of EHDP on Pi, red cell 2, 
3-DPG and P50 of ODC.25 Furthermore, the lack of changes in 
mean glucose and HbA1c indicated an interesting association 
between improvement in retinopathy as evaluated by retinal 
fluorescein angiography and increased Pi (P  0.05).
Potential therapeutic application  
of fructose-1, 6-diphosphate
Fructose-1, 6-diphosphate (FDP) is a key intermediate in 
anaerobic glycolysis and is the product of the major regula-
tory enzyme in the pathway (phosphofructokinase). Natelson 
et al26 showed that orally administrated fructose diphosphate 
calcium salt was absorbed directly by the intestinal tract 
without splitting the phosphate linkage, and that 6 g led to 
an increase of serum inorganic phosphate averaging 15%, 
citric acid 10.7%, and nonprotein organic phosphate as much 
as 173%. Further preclinical and clinical data indicate that 
FDP can enter cells and serve as a metabolizable substrate 
of glycolysis.27–29 FDP acts as human bioenergy and can 
transport phosphorous intracellularly as well as deliver 
4 moles of ATP per mole of FDP. Thus FDP has substantial 
cytoprotective effects on a variety of ischemia-induced tissue 
damage.30,31 Recent studies also show that FDP can modulate 
nitric oxide production in a variety of cellular injury events, 
and indicate that FDP can influence red cell rheology and 
can increase red cell ATP and 2, 3-DPG levels.32–34 FDP can 
be given orally and intravenously to humans and it is well Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 176
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tolerated at pharmacological doses. Although FDP appears 
to be highly efficacious, no previous controlled study has 
been reported in diabetic patients.
Discussion
This review demonstrates a close correlation between 
plasma concentration of Pi and the degree of metabolic 
control of diabetes. The relationship may involve Pi 
handling in the kidney tubules; the major regulator of Pi 
homeostasis. Glucose and Pi (eg, alanine, myoinositol) 
reabsorption are all examples of secondary active trans-
port processes with sodium (Na+) as the driving force. 
The sodium entry results from the active extrusion of Na+ 
across the basolateral segment of the proximal tubular cells, 
energized by adenosine triphosphate (ATP) hydrolysis, and 
catalyzed by the Na/K-ATPase. As glucose is more potent 
than inorganic phosphate in stimulating the uptake of Na+ 
in renal microvillus vesicles,35 the elevated glucose con-
centrations depolarize the transmembrane electrochemical 
Na+ gradient of the brush border membrane for inorganic 
phosphate entry into the tubular cells and decrease 
intracellular phosphate leading to hyperphosphaturia. 
Therefore normalization of blood glucose levels leads to an 
improved capacity of the kidney tubules to reabsorb Pi and 
a subsequent increase in plasma Pi concentration. Over time 
this improved glucose regulation will positively influence 
or even prevent the long-term diabetic complications as has 
been proven in DCCT and UKPDS studies.36,37 Although 
effective, however, this method achieves only an approxi-
mation of normalcy given the chronic and fluctuating 
nature of diabetes and the nonphysiologic administration 
of daily injections vs immediate insulin secretion into the 
portal circulation in response to a rise in blood glucose in 
healthy organisms.
Increasing the dietary intake of Pi with 6 g of calcium 
diphosphate has been shown to be of no benefit since the 
maximal reabsorptive capacity for Pi in the kidney tubules 
does not increase, but actually decreases leading to a signifi-
cant increase in Pi clearance (Figure 1).20 This effect was not 
found to be related to the serum level of parathyroid hormone 
or growth hormone, but inversely correlated with the degree 
of hyperglycemia.
The study of the effect of etidronate disodium (EHDP) 
superficially appears to be more promising since EHDP 
increased both plasma Pi and red cell 2, 3-diphophoglycerate 
levels and thereby the oxygen release capacity. Studies 
of nonproliferative retinopathy suggested that a 6-month 
course of EHDP administration may improve retinopathy.25 
EHDP in large doses may also suppress bone turnover, 
inhibits bone mineralization and affect tooth development, 
deleterious effects that discourage general use.38,39
The therapeutic use of fructose-1, 6 diphosphate (FDP) 
in diabetes is much more attractive since it is a natural 
intermediate in glycolysis and also acts as human bioenergy, 
delivering intracellular phosphorus and 4 moles ATP per mole 
of FDP. The substance is well tolerated at pharmacological 
doses and can be given orally. Future controlled studies may 
lead to a prophylactic therapy to prevent vascular complications 
and may also counteract the metabolic disturbances leading to 
type 2 diabetes and the metabolic syndrome.40
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